As April draws to a close, it's time to focus on the biotech stocks facing regulatory catalyst in the month of May. The FDA approved eight novel drugs last May, taking the total number of approvals for the year to 55.
So far this year, 11 novel drugs have secured the regulatory nod. Can 2024 surpass the tally set last year?
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com